|Bid||230.01 x 800|
|Ask||229.77 x 800|
|Day's Range||229.10 - 234.05|
|52 Week Range||163.08 - 247.64|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||63.28|
|Earnings Date||Jan 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||250.74|
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Edwards Lifesciences stock tumbled Thursday after an analyst suggested sales of the company's heart-valve replacements, using a technique called TAVR, are experiencing a slowdown.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2019 after the market closes on Thursday, January 30, 2020, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.
Boosted by average EPS growth of 84% over the last three quarters, life sciences leader and biologic drugmaker Repligen is now testing a new buy point.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, January 13, 2020.
In 2000 Mike Mussallem was appointed CEO of Edwards Lifesciences Corporation (NYSE:EW). This analysis aims first to...
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. That's why we weren't […]
Dow futures: Will a not-so-forceful Star Wars lift or sink Disney stock? Also, Applied Materials, KLA, Inphi, Keysight Technologies and Edwards Lifesciences have new buy points.
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?
Edwards Lifesciences (EW) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.